SANTARUS LAUNCHES ZEGERID CAPSULES IN THE U.S.

Tuesday morning, Santarus, Inc., a pharmaceutical company, announced that it had floated ZEGERID Capsules 40 mg/1100 mg and 20 mg/1100 mg, an immediate-release proton pump inhibitor in the U.S market. The U.S. Food and Drug Administration approved ZEGERID Capsules on February 27, 2006, i.e. yesterday.
Trading Markets